Veracyte, Inc.
VCYT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.96 | -0.27 | 0.86 | -0.56 |
| FCF Yield | 2.11% | 1.71% | -0.06% | -1.32% |
| EV / EBITDA | 57.73 | -36.32 | -223.22 | -43.91 |
| Quality | ||||
| ROIC | 1.23% | -7.87% | -3.74% | -6.70% |
| Gross Margin | 64.95% | 68.73% | 65.74% | 66.11% |
| Cash Conversion Ratio | 3.11 | -0.59 | -0.21 | 0.42 |
| Growth | ||||
| Revenue 3-Year CAGR | 14.55% | 18.04% | 36.16% | 22.18% |
| Free Cash Flow Growth | 86.24% | 3,478.80% | 97.26% | -194.84% |
| Safety | ||||
| Net Debt / EBITDA | -3.83 | 4.13 | 19.99 | 2.56 |
| Interest Coverage | 8,071.00 | -5,719.67 | -207.48 | -339.85 |
| Efficiency | ||||
| Inventory Turnover | 7.18 | 7.00 | 7.11 | 6.63 |
| Cash Conversion Cycle | 68.74 | 51.12 | 62.75 | 63.37 |